Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal epithelial cell mucins and glycolipids constitute the primary biochemical and physical barrier of the gastrointestinal tract. Mucins are large, heavily glycosylated proteins; MUC2 is the primary secreted mucin forming the protective mucus gel, while membrane-bound mucins like MUC1 and MUC13 contribute to the glycocalyx (Johansson et al., 2011, Nature Reviews Gastroenterology & Hepatology). Glycolipids, including glycosphingolipids and gangliosides, are integral components of the apical membrane that facilitate cell signaling and serve as attachment sites for both commensal bacteria and pathogens (Varki et al., 2015, Essentials of Glycobiology). These molecules are critical in preventing the translocation of gut microbes and protecting the underlying epithelium from mechanical stress and enzymatic digestion. In pathological states such as ulcerative colitis or Crohn's disease, the composition and thickness of the mucin layer are often significantly altered, leading to increased intestinal permeability and inflammation (Boltin et al., 2013, Journal of Clinical Gastroenterology). Therapeutic interventions often target these components to restore barrier integrity or to block the adhesion of toxins and pathogens, such as the binding of Cholera toxin to GM1 gangliosides.
Enhancement of mucus secretion, competitive inhibition of pathogen attachment (anti-adhesion), and formation of a protective physical complex over the epithelial surface.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal epithelial cell mucins and glycolipids.